Talaris Therapeutics, a biotechnology company, completed the merger with Tourmaline Bio, a late-stage clinical biotechnology company. Financial terms were not disclosed. “We are thrilled to close this transaction and move Tourmaline into its next phase as a public company, leading an IL-6 renaissance and continuing to accelerate TOUR006 through late-stage clinical trials in TED, ASCVD and other diseases,” Sandeep Kulkarni, Tourmaline Managing Director and CEO.